Prostate Cell News Volume 3.26 | Jul 13 2012

Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) on Growth and Invasiveness of PC3 Human Prostate Cancer
Investigators determined the effect of GHRH antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the evaluation of various factors that contribute largely to the progression of prostate cancer. [Int J Cancer] Abstract

LABORATORY RESEARCH

Acetylation-Dependent Regulation of Skp2 Function
Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Scientists identified an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provided insight into how cytoplasmic Skp2 controls cellular migration. [Cell] Abstract

First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Down-Regulation in Human Neoplasm. Implication for Resistance to Therapeutics in Prostate Cancer
Researchers reported, for the first time, of sphingosine 1-phosphate lyase protein expression and enzymatic activity in human neoplasm. [Mol Cancer Ther] Abstract

Akt1 Mediates Prostate Cancer Cell Microinvasion and Chemotaxis to Metastatic Stimuli via Integrin β3 Affinity Modulation
Using functional and biochemical approaches, scientists examined the role of Akt1 in the affinity modulation of integrin β3 in prostate cancer cells. [Brit J Cancer] Abstract

Resistance to the mTOR-Inhibitor RAD001 Elevates Integrin α2- and β1-Triggered Motility, Migration and Invasion of Prostate Cancer Cells
Researchers investigated the metastatic potential of PC3 prostate cancer cells, susceptible or resistant to the mammalian target of rapamycin (mTOR)-inhibitor RAD001. [Brit J Cancer] Abstract

Antiandrogen Gold Nanoparticles Dual-Target and Overcome Treatment Resistance in Hormone-Insensitive Prostate Cancer Cells
Investigators showed that antiandrogen gold nanoparticles selectively engage two distinct receptors, androgen receptor and G-protein coupled receptor 6A, which are upregulated in prostate cancer. [Bioconjug Chem] Abstract

Direct Cooperation between Androgen Receptor and E2F1 Reveals a Common Regulation Mechanism for Androgen-Responsive Genes in Prostate Cells
Researchers showed that ATAD2 gene expression is directly regulated by androgen receptor (AR) via an AR binding sequence located in the distal enhancer of its regulatory region. [Mol Endocrinol] Abstract

Implication of Pleiotrophin in Human PC3 Prostate Cancer Cell Growth In Vivo
Scientists studied the role of endogenous pleiotrophin in human prostate cancer growth in vivo. [Cancer Sci] Abstract

Suppression of CX43 Expression and Promotion of Prostate Cancer Cell Progression by miR-20a.
Investigators showed that microRNA-20a (miR-20a) significantly contributes to the progression of prostate cancer by targeting a gap junction protein, alpha 1 (CX43). . [Cancer Biol Ther] Abstract

VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-1R Define a Novel Mechanism of Aggressive Prostate Cancer
Scientists demonstrated that the VEGF receptor, neuropilin-2 is associated with high-grade, PTEN-null prostate cancer and that its expression in tumor cells is induced by PTEN loss as a consequence of c-Jun activation. [Cancer Discov] Abstract

CLINICAL RESEARCH

Effect of Abiraterone Acetate plus Prednisone on the QT Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
This open-label, single-arm phase Ib study was conducted to assess the effect of abiraterone acetate and abiraterone on the QT interval. [Cancer Chemoth Pharm] Abstract

Phase I Study of Sorafenib in Combination with Docetaxel and Prednisone in Chemo-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer
Investigators performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. [Cancer Chemoth Pharm] Abstract

Preliminary Results of Intensity-Modulated Radiation Therapy with Helical Tomotherapy for Prostate Cancer
Researchers presented the preliminary results of intensity-modulated radiation therapy with helical tomotherapy for clinically localized prostate cancer. [J Cancer Res Clin Oncol] Abstract

ULM Pharmacy Professors Awarded U.S. Patent for New Drug
The United States (U.S.) Patent & Trademark Office recently awarded the University of Louisiana at Monroe (ULM) College of Pharmacy a patent for a new anti-cancer drug designed to control prostate cancer metastasis. [The University of Louisiana at Monroe] Press Release

Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase I Clinical Trial
Arrowhead Research Corporation announced that the first patient has been dosed in a Phase I clinical trial with Adipotide®. The Phase I trial is designed to evaluate a single 28 day cycle of Adipotide in patients with castrate-resistant prostate cancer and no standard treatment options. [Arrowhead Research Corporation] Press Release

Nymox Announces Completion of Enrollment for Phase III BPH Re-Injection Study
Nymox Pharmaceutical Corporation announced the completion of enrollment for Study NX02-0020, one of the Company’s Phase III studies of NX-1207 for benign prostatic hyperplasia (BPH). [Nymox Pharmaceutical Corporation] Press Release

Biomedical Engineering Degree First In Western Canada
The University of Victoria is launching a new undergraduate biomedical engineering degree, the first of its kind west of Ontario. [The University of Victoria] Press Release

Death of Evidence Announcement
To make the public aware of government cuts to federal science programs, Canadians organized a ‘Death of Evidence’ rally to coincide with a large scientific conference taking place in Ottawa. [Death of Evidence, Canada] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 2012 International Forum on Stem Cells
November 2-3, 2012
Tianjin, China

Visit our events page to see a complete list of events in the prostate cell community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Postdoctoral Position – Cancer Genomics (University of California)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Molecular Biology and Genomics (University Hospital Zurich)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.